Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Dyne Therapeutics Inc (NASDAQ: DYN) closed at $23.55 down -0.34% from its previous closing price of $23.63. In other words, the price has decreased by -$0.34 from its previous closing price. On the day, 2.23 million shares were traded. DYN stock price reached its highest trading level at $24.105 during the session, while it also had its lowest trading level at $23.26.
Ratios:
For a deeper understanding of Dyne Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.83 and its Current Ratio is at 16.83. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
On August 25, 2025, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $35.
On June 24, 2025, Bernstein started tracking the stock assigning a Mkt Perform rating and target price of $13.Bernstein initiated its Mkt Perform rating on June 24, 2025, with a $13 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 05 ’25 when Cox John sold 2,640 shares for $13.41 per share. The transaction valued at 35,402 led to the insider holds 199,539 shares of the business.
Friedl-Naderer Johanna sold 894 shares of DYN for $11,863 on Sep 04 ’25. The Chief Commercial Officer now owns 95,017 shares after completing the transaction at $13.27 per share. On Sep 05 ’25, another insider, Friedl-Naderer Johanna, who serves as the Chief Commercial Officer of the company, sold 144 shares for $13.41 each. As a result, the insider received 1,931 and left with 94,873 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DYN now has a Market Capitalization of 3350311168 and an Enterprise Value of 2787463168.
Stock Price History:
The Beta on a monthly basis for DYN is 1.22, which has changed by -0.18058455 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, DYN has reached a high of $35.68, while it has fallen to a 52-week low of $6.36. The 50-Day Moving Average of the stock is 60.10%, while the 200-Day Moving Average is calculated to be 90.75%.
Shares Statistics:
For the past three months, DYN has traded an average of 2.80M shares per day and 3349920 over the past ten days. A total of 114.34M shares are outstanding, with a floating share count of 109.62M. Insiders hold about 22.94% of the company’s shares, while institutions hold 71.87% stake in the company. Shares short for DYN as of 1760486400 were 17097410 with a Short Ratio of 6.11, compared to 1757894400 on 15303535. Therefore, it implies a Short% of Shares Outstanding of 17097410 and a Short% of Float of 13.420000000000002.
Earnings Estimates
The stock of Dyne Therapeutics Inc (DYN) is currently in the spotlight, with 11.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.83, with high estimates of -$0.64 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$3.21 and -$4.37 for the fiscal current year, implying an average EPS of -$3.66. EPS for the following year is -$3.54, with 13.0 analysts recommending between -$2.81 and -$4.95.
